Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2021 | Retinal Disorders

Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy

Authors: Young Ho Kim, Boram Lee, Edward Kang, Jaeryung Oh

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2021

Abstract

Purpose

To investigate the relationship between choroidal thickness (CT) profile and clinical outcomes after anti-vascular endothelial growth factor (VEGF) treatment in polypoidal choroidal vasculopathy (PCV).

Methods

Medical records of patients diagnosed with PCV who received anti-VEGF treatment over 12 months were reviewed. Subfoveal CT (SFCT) and peripapillary CT (PCT) were measured on swept-source optical coherence tomography images. Patients were divided into various groups based on choroidal profiles including SFCT, nasal PCT (nPCT) and ratio of SFCT to nPCT (SFCT/nPCT). Clinical outcomes were compared between the thin and thick CT groups.

Results

A total of 65 patients with PCV patients were included. After ant-VEGF treatment, SFCT was significantly decreased after anti-VEGF treatment (P = 0.001), but nasal PCT (nPCT) was not. Clinical outcomes were not different between the thin and thick SFCT groups. Total number of injections during the 12 months was significantly fewer in the thin nPCT group (3.4 ± 1.3) than in the thick nPCT group (4.5 ± 1.8) (P = 0.020). Complete resolution after loading injections was more frequently observed in the high SFCT/nPCT ratio (> 1.9) group (87.9%) than in the low SFCT/nPCT ratio (≤ 1.90) group (59.4%) (P = 0.009). The ratio of SFCT/nPCT showed the best predictive ability for poor responders (area under curve = 0.771).

Conclusion

These results suggest that baseline nPCT and SFCT/nPCT ratio could be a good biomarker that reflects clinical outcomes after anti-VEGF treatment in PCV.

Available only for authorised users

Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110. https://doi.org/10.1097/00006982-199515020-00003CrossRefPubMed

Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8CrossRef

Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139. https://doi.org/10.1016/j.preteyeres.2016.04.002CrossRefPubMed

Lee J, Byeon SH (2019) Prevalence and clinical characteristics of pachydrusen in polypoidal choroidal vasculopathy: multimodal image study. Retina 39:670–678. https://doi.org/10.1097/iae.0000000000002019CrossRefPubMed

Ting DS, Ng WY, Ng SR, Tan SP, Yeo IY, Mathur R, Chan CM, Tan AC, Tan GS, Wong TY, Cheung CM (2016) Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 164:128–136.e121. https://doi.org/10.1016/j.ajo.2015.12.024CrossRefPubMed

Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118:840–845. https://doi.org/10.1016/j.ophtha.2010.09.012CrossRefPubMed

Gupta P, Ting DSW, Thakku SG, Wong TY, Cheng CY, Wong E, Mathur R, Wong D, Yeo I, Gemmy Cheung CM (2017) Detailed characterization of choroidal morphologic and vascular features in age-related macular degeneration and polypoidal choroidal vasculopathy. Retina 37:2269–2280. https://doi.org/10.1097/iae.0000000000001481CrossRefPubMed

Chang YC, Cheng CK (2020) Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina. 40:1403–1411. https://doi.org/10.1097/iae.0000000000002583CrossRefPubMed

Hayreh SS (2004) Posterior ciliary artery circulation in health and disease: the Weisenfeld lecture. Invest Ophthalmol Vis Sci 45:749–757; 748. https://doi.org/10.1167/iovs.03-0469CrossRefPubMed

10.

Yun C, Oh J, Ahn SE, Hwang SY, Kim SW, Huh K (2016) Peripapillary choroidal thickness in patients with early age-related macular degeneration and reticular pseudodrusen. Graefes Arch Clin Exp Ophthalmol 254:427–435. https://doi.org/10.1007/s00417-015-3054-7CrossRefPubMed

11.

Kang HM, Kim EW, Choi JH, Koh HJ, Lee SC (2020) Focal lamina cribrosa defects and significant peripapillary choroidal thinning in patients with unilateral branch retinal vein occlusion. PLoS One 15:e0230293. https://doi.org/10.1371/journal.pone.0230293CrossRefPubMedPubMedCentral

12.

Yun C, Oh J, Han JY, Hwang SY, Moon SW, Huh K (2015) Peripapillary choroidal thickness in central serous chorioretinopathy: is choroid outside the macula also thick? Retina 35:1860–1866. https://doi.org/10.1097/iae.0000000000000539CrossRefPubMed

13.

Nam KT, Chung HW, Jang S, Kim SW, Oh J, Yun C (2020) Features of the macular and peripapillary choroid and choriocapillaris in eyes with nonexudative age-related macular degeneration. Retina 40:2270–2276. https://doi.org/10.1097/iae.0000000000002758CrossRefPubMed

14.

Lee KH, Kim SH, Lee JM, Kang EC, Koh HJ (2017) Peripapillary choroidal thickness change of polypoidal choroidal vasculopathy after anti-vascular endothelial growth factor. Korean J Ophthalmol 31:431–438. https://doi.org/10.3341/kjo.2016.0101CrossRefPubMedPubMedCentral

15.

Lee B, Yoo G, Yun C, Oh J (2019) Short-term effects of anti-vascular endothelial growth factor on peripapillary choroid and choriocapillaris in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 257:2163–2172. https://doi.org/10.1007/s00417-019-04432-wCrossRefPubMed

16.

Miyake M, Ooto S, Yamashiro K, Takahashi A, Yoshikawa M, Akagi-Kurashige Y, Ueda-Arakawa N, Oishi A, Nakanishi H, Tamura H, Tsujikawa A, Yoshimura N (2015) Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204. https://doi.org/10.1038/srep16204CrossRefPubMedPubMedCentral

17.

Kim H, Lee SC, Kwon KY, Lee JH, Koh HJ, Byeon SH, Kim SS, Kim M, Lee CS (2016) Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 254:1497–1503. https://doi.org/10.1007/s00417-015-3221-xCrossRefPubMed

18.

Kim JH, Lee TG, Chang YS, Kim CG, Cho SW (2016) Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Br J Ophthalmol 100:1634–1639. https://doi.org/10.1136/bjophthalmol-2015-308074CrossRefPubMed

19.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2015) Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol 99:1284–1288. https://doi.org/10.1136/bjophthalmol-2014-306432CrossRefPubMed

20.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, Sekiryu T, Okada AA, Iida T (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159:627–633. https://doi.org/10.1016/j.ajo.2014.12.025CrossRefPubMed

21.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123:617–624. https://doi.org/10.1016/j.ophtha.2015.10.039CrossRefPubMed

22.

Nagai N, Suzuki M, Minami S, Kurihara T, Kamoshita M, Sonobe H, Watanabe K, Uchida A, Shinoda H, Tsubota K, Ozawa Y (2019) Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep 9:11389. https://doi.org/10.1038/s41598-019-47738-9CrossRefPubMedPubMedCentral

23.

Padron-Perez N, Arias L, Rubio M, Lorenzo D, Garcia-Bru P, Catala-Mora J, Caminal JM (2018) Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci 59:1119–1124. https://doi.org/10.1167/iovs.17-22144CrossRefPubMed

24.

Jang JW, Kim JM, Kang SW, Kim SJ, Bae K, Kim KT (2019) Typical polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization. Retina 39:1995–2003. https://doi.org/10.1097/iae.0000000000002259CrossRefPubMed

25.

Shin JY, Kwon KY, Byeon SH (2015) Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Acta Ophthalmol 93:524–532. https://doi.org/10.1111/aos.12653CrossRefPubMed

26.

Tan CS, Ouyang Y, Ruiz H, Sadda SR (2012) Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:261–266. https://doi.org/10.1167/iovs.11-8782CrossRefPubMed

27.

Sizmaz S, Kucukerdonmez C, Pinarci EY, Karalezli A, Canan H, Yilmaz G (2013) The effect of smoking on choroidal thickness measured by optical coherence tomography. Br J Ophthalmol 97:601–604. https://doi.org/10.1136/bjophthalmol-2012-302393CrossRefPubMed

28.

Lee M, Lee H, Kim HC, Chung H (2018) Changes in stromal and luminal areas of the choroid in pachychoroid diseases: insights into the pathophysiology of pachychoroid diseases. Invest Ophthalmol Vis Sci 59:4896–4908. https://doi.org/10.1167/iovs.18-25018CrossRefPubMed

29.

Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594–603.e591. https://doi.org/10.1016/j.ajo.2010.10.030CrossRefPubMed

30.

Cho HJ, Kim HS, Jang YS, Han JI, Lew YJ, Lee TG, Kim CG, Kim JW (2013) Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:1192–1200.e1191. https://doi.org/10.1016/j.ajo.2013.07.001CrossRefPubMed

31.

Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, Yoshimura N (2012) Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 53:3663–3672. https://doi.org/10.1167/iovs.12-9619CrossRefPubMed

Title: Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy
Authors: Young Ho Kim
Boram Lee
Edward Kang
Jaeryung Oh
Publication date: 01-07-2021
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2021
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-05051-6

At a glance: The STEP trials

Springer Medicine

Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2021

Letter to the Editor relating to Graefe’s Arch Clin Exp Ophthalmol. 2020 June. “Medical management of pediatric glaucoma: lessons learned from randomized clinical trials”

Monocular and binocular visual parameters associated to vision-related quality of life in patients with epiretinal membrane: a prospective cohort

Comparability of corneal thickness and opacity depth assessed by OCT and UBM

Retinal venous pressure is decreased after anti-VEGF therapy in patients with retinal vein occlusion–related macular edema

Global multi-site, prospective analysis of cataract surgery outcomes following ICHOM standards: the European CAT-Community

Outcomes after Descemet membrane endothelial keratoplasty over a period of 7 years at a tertiary referral center: endothelial cell density, central corneal thickness, and visual acuity